Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Alexandria Real Estate Equities Inc.

Ultragenyx Pharmaceutical ( ($RARE) ) has shared an update. On February 3, 2026, Ultragenyx Pharmaceutical reported new long-term clinical data for...

Ultragenyx Highlights New UX111 Data in FDA Resubmission

Carter Bankshares ( ($CARE) ) has shared an update. On February 2, 2026, Carter Bankshares, Inc. announced that its board of directors had authoriz...

Carter Bankshares Announces $10 Million Share Repurchase Program

These are the upcoming stock splits for the week of February 2 to February 6, based on&nbsp;TipRanks’ Stock Splits Calendar. A stock split is basic...

Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested

Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on New World Development (NWWDF – Research Report) a...

Analysts Offer Insights on Real Estate Companies: New World Development (OtherNWWDF) and Alexandria Equities (ARE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on High Tide (HITI – Research Report), Ultragenyx Pharm...

Analysts Offer Insights on Healthcare Companies: High Tide (HITI), Ultragenyx Pharmaceutical (RARE) and Kymera Therapeutics (KYMR)

The latest announcement is out from Daré Bioscience ( ($DARE) ). On January 23, 2026, Daré Bioscience filed a Certificate of Designation in Delawar...

Daré Bioscience Launches Regulation A Preferred Unit Offering

The SPDR S&P 500 ETF Trust ($SPY) is up 0.28% in the pre-market trading session on Wednesday, primarily driven by strong gains in major technology ...

SPY ETF Daily Update, 1/28/2026

Evercore ISI analyst James Kammert maintained a Buy rating on Alexandria Equities yesterday and set a price target of $64.00. The company’s shares ...

Evercore ISI Sticks to Their Buy Rating for Alexandria Equities (ARE)

The Vanguard S&P 500 ETF (VOO), which tracks the S&P 500 Index (SPX), was up about 0.27% in premarket trading on Tuesday, supported by gains in maj...

Vanguard S&P 500 ETF (VOO) Daily Update, 1/27/2026

Barclays analyst maintained a Hold rating on Alexandria Equities today and set a price target of $41.00. Alexandria Equities has an analyst consens...

Alexandria Equities (ARE) Receives a Hold from Barclays

An announcement from Tactical Resources Corp. ( ($TSE:RARE) ) is now available. Tactical Resources Corp. plans to raise up to C$2 million through a...

Tactical Resources Launches $2 Million Private Placement to Fund Rare Earth Initiatives

J.P. Morgan analyst Anthony Paolone maintained a Hold rating on Alexandria Equities yesterday and set a price target of $63.00. According to TipRan...

J.P. Morgan Remains a Hold on Alexandria Equities (ARE)

American Rebel Holdings ( ($AREB) ) has shared an update. In early January 2026, American Rebel Holdings entered a series of balance-sheet-focused ...

American Rebel Holdings Executes January 2026 Capital Restructuring

Earnings reports, acquisitions, and more make up the top stock market happenings on Tuesday.


Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Ares Management’s ($ARES) shares edged higher early Tuesday after the alternative asset manager announced raising about $7.1 billion in new capital...

Ares Stock Rises after $7B Capital Raise to Buy Existing Private Loan Portfolios

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report), ...

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Dexcom (DXCM) and Health Catalyst (HCAT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inogen (INGN – Research Report), Exelixis (EXEL – ...

Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE)

OpenAI and SoftBank ($SFTBY) ($SFTBF) are deepening their long-term bet on AI infrastructure, investing $1 billion in SB Energy to support the expa...

OpenAI and SoftBank Double Down on AI Data Center Expansion

Altareit SA ( ($FR:AREIT) ) has shared an announcement. Altareit reported that as of the end of December 2025 it held 192 treasury shares, represen...

Altareit Reports Neutral Treasury Share Activity in December 2025

In a report released today, Benjamin Budish from Barclays maintained a Buy rating on Ares Management, with a price target of $222.00. According to ...

Barclays Remains a Buy on Ares Management (ARES)

The latest announcement is out from Aecon Group Inc. ( ($TSE:ARE) ). Aecon Group Inc. has scheduled the release of its fourth quarter and full-year...

Aecon Sets March 2026 Date for Q4 and Year-End 2025 Results and Investor Call

Lake Street analyst Ryan Meyers maintained a Buy rating on The Arena Group today and set a price target of $10.00. Meyers covers the Consumer Cycli...

Lake Street Sticks to Its Buy Rating for The Arena Group (AREN)

The Arena Group ( ($AREN) ) has issued an announcement. On December 31, 2025, The Arena Group amended two major debt facilities, extending maturiti...

Arena Group Extends Debt Maturities in Refinancing Move

In a report released on January 5, Sabahat Khan from RBC Capital maintained a Hold rating on Aecon Group Inc., with a price target of C$30.00. The ...

RBC Capital Sticks to Their Hold Rating for Aecon Group Inc. (ARE)

Alexandria Real Estate Equities faces a securities lawsuit after a $323.9M Long Island City impairment, with investors alleging executives misled t...

Life-Science REIT Sector Faces Scrutiny After Alexandria Real Estate Securities Lawsuit

The latest announcement is out from Aecon Group Inc. ( ($TSE:ARE) ). Aecon Group Inc.’s utilities subsidiary has closed the acquisition of KPC, an ...

Aecon Utilities Closes Acquisition of High-Voltage Specialist KPC to Boost Grid Modernization Play

Arecor Therapeutics PLC ( ($GB:AREC) ) just unveiled an announcement. Arecor Therapeutics has announced that it will co-host a virtual fireside pan...

Arecor and Sequel Med Tech to Host Virtual Panel on Future of Diabetes Treatment

In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $50.00. Nochom...

Current Quarter	$1.78	Next Quarter	$1.65
Current Year	$6.43	Next Year	$6.02
QoQ Growth	-7.3%	YoY Growth	-6.4%
3Y EPS CAGR	-22.3%	Target Price	$59.75
Consensus	Buy	Upside	+10.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARE	$53.94	-0.39%	1.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARE	$53.94	-0.4%	1.40M
3
4
5
6

ARE

ARE

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Alexandria Real Estate Equities Inc. Data in Excel

Get Alexandria Real Estate Equities Inc. Data in Excel